Michal Shteinberg

5.8k total citations · 2 hit papers
110 papers, 2.2k citations indexed

About

Michal Shteinberg is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Emergency Medical Services. According to data from OpenAlex, Michal Shteinberg has authored 110 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Pulmonary and Respiratory Medicine, 25 papers in Epidemiology and 12 papers in Emergency Medical Services. Recurrent topics in Michal Shteinberg's work include Cystic Fibrosis Research Advances (70 papers), Neonatal Respiratory Health Research (38 papers) and Tracheal and airway disorders (20 papers). Michal Shteinberg is often cited by papers focused on Cystic Fibrosis Research Advances (70 papers), Neonatal Respiratory Health Research (38 papers) and Tracheal and airway disorders (20 papers). Michal Shteinberg collaborates with scholars based in Israel, United Kingdom and Italy. Michal Shteinberg's co-authors include Jane C. Davies, Iram Haq, Deepika Polineni, Avram Hershko, Jennifer L. Taylor‐Cousar, James D. Chalmers, Michael Brandeis, Tamar Listovsky, Stefano Aliberti and Zeev Blumenfeld and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Michal Shteinberg

93 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cystic fibrosis

2021 411 citations Michal Shteinberg, Jane C. Davies et al. The Lancet profile →
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis

2025 26 citations James D. Chalmers, Pierre‐Régis Burgel et al. New England Journal of Medicine profile →

Peers

Michal Shteinberg

PRM

EPIDE

PHYSI

Tomoyuki Kakugawa Japan

Shuichi Abe Japan

Robert J. Kaner United States

Simon P. Hart United Kingdom

Kazuyoshi Kurashima Japan

Yuji Ishimatsu Japan

Marco Cipolli Italy

Jason S. Debley United States

Malena Cohen‐Cymberknoh Israel

Serena Quattrucci Italy

Tomoyuki Kakugawa Japan

Michal Shteinberg

1.1k ×0.9

PRM

285 ×0.6

484 ×1.6

EPIDE

61 ×0.2

321 ×1.8

PHYSI

Citations per year, relative to Michal Shteinberg Michal Shteinberg (= 1×) peers Tomoyuki Kakugawa

Countries citing papers authored by Michal Shteinberg

Since Specialization

Citations

This map shows the geographic impact of Michal Shteinberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michal Shteinberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michal Shteinberg more than expected).

Fields of papers citing papers by Michal Shteinberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michal Shteinberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michal Shteinberg. The network helps show where Michal Shteinberg may publish in the future.

Co-authorship network of co-authors of Michal Shteinberg

This figure shows the co-authorship network connecting the top 25 collaborators of Michal Shteinberg. A scholar is included among the top collaborators of Michal Shteinberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michal Shteinberg. Michal Shteinberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chalmers, James D., Michal Shteinberg, Sanjay H. Chotirmall, et al.. (2025). Study Design of a Phase III Study (AIRTIVITY®) of the Novel Cathepsin C (Dipeptidyl Peptidase 1) Inhibitor BI 1291583 in People With Bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 211(Supplement_1). A1964–A1964. 1 indexed citations

Qvist, Tavs, Andrew Bush, & Michal Shteinberg. (2025). Water, Water Everywhere, Nor Any Drop to Drink: Beware of Mycobacteria. American Journal of Respiratory and Critical Care Medicine. 211(5). 691–692.

Chalmers, James D., Pierre‐Régis Burgel, Charles L. Daley, et al.. (2025). Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. New England Journal of Medicine. 392(16). 1569–1581. 26 indexed citations breakdown →

Perea, Lídia, Jennifer S. Pollock, Chloe Hughes, et al.. (2024). Changes in Blood Immune Cell Transcriptomes Associate With Disease Severity, Infection, and Inflammation in Bronchiectasis Patients: Data From the EMBARC-BRIDGE Study. A1030–A1030.

Shteinberg, Michal, Inbal Golan‐Tripto, Galit Livnat, et al.. (2024). Treatment effects of elexacaftor/tezacaftor/ivacaftor on people with cystic fibrosis heterozygous for 3849+10kbC->T and a class I variant. Journal of Cystic Fibrosis. 24(3). 548–551.

Aliberti, Stefano, Francesco Blasi, Pierre‐Régis Burgel, et al.. (2024). Mycobacterium aviumcomplex pulmonary disease patients with limited treatment options. ERJ Open Research. 10(1). 610–2023. 2 indexed citations

Chalmers, James D., Marcus Mall, Pamela J. McShane, et al.. (2024). A systematic literature review of the clinical and socioeconomic burden of bronchiectasis. European Respiratory Review. 33(173). 240049–240049. 8 indexed citations

Perea, Lídia, Mathieu Bottier, Erin Cant, et al.. (2024). Airway IL-1β is related to disease severity and mucociliary function in bronchiectasis. European Respiratory Journal. 64(2). 2301966–2301966. 14 indexed citations

Najjar‐Debbiny, Ronza, Ofra Barnett‐Griness, Johad Khoury, et al.. (2023). Association Between COVID-19 Infection and Pulmonary Fibrosis: A Nested Case-Control Study. The American Journal of Medicine. 136(11). 1087–1093.e2. 7 indexed citations

10.

Taylor‐Cousar, Jennifer L., Paul D. Robinson, Michal Shteinberg, & D.G. Downey. (2023). CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis. The Lancet. 402(10408). 1171–1184. 68 indexed citations

11.

Shteinberg, Michal, Oriol Sibila, Nili Stein, et al.. (2023). Risk of SARS-CoV-2 Infection and Disease Severity Among People With Bronchiectasis. CHEST Journal. 165(1). 79–83. 4 indexed citations

12.

Taylor‐Cousar, Jennifer L., Rachel Janney, Peter G. Middleton, et al.. (2023). A provider survey assessing fetal impact of CFTR modulator use in males with CF during assisted and unassisted reproduction and partner pregnancy. Journal of Cystic Fibrosis. 23(3). 412–416. 4 indexed citations

13.

Livnat, Galit, Adi Dagan, Einat Shmueli, et al.. (2022). Treatment effects of Elexacaftor/Tezacaftor/Ivacaftor in people with CF carrying non-F508del mutations. Journal of Cystic Fibrosis. 22(3). 450–455. 7 indexed citations

14.

Koren, Ilana, et al.. (2022). Real life evaluation of the multi-organ effects of Lumacaftor/Ivacaftor on F508del homozygous cystic fibrosis patients. BMC Pharmacology and Toxicology. 23(1). 80–80. 5 indexed citations

15.

Livnat, Galit, et al.. (2022). Respiratory healthcare professionals’ views on long-term recommendations of interventions to prevent acute respiratory illnesses after the COVID-19 pandemic. ERJ Open Research. 8(4). 114–2022. 1 indexed citations

16.

Byrnes, Catherine A., Jane C. Davies, Madhulika Kabra, et al.. (2020). ‘Go for it, dream big, work hard and persist’: A message to the next generation of CF leaders in recognition of International Women's Day 2020. Journal of Cystic Fibrosis. 19(2). 184–193. 1 indexed citations

17.

Shteinberg, Michal, Jeanette Boyd, Stefano Aliberti, et al.. (2020). What is important for people with nontuberculous mycobacterial disease? An EMBARC-ELF patient survey. ERJ Open Research. 7(1). 807–2020. 9 indexed citations

18.

Dagan, Adi, Malena Cohen‐Cymberknoh, Michal Shteinberg, et al.. (2017). Ivacaftor for the p.Ser549Arg (S549R) gating mutation – The Israeli experience. Respiratory Medicine. 131. 225–228. 21 indexed citations

19.

Shteinberg, Michal, Michael Wilschanski, Aurélie Hatton, et al.. (2016). Changes of CFTR functional measurements and clinical improvements in cystic fibrosis patients with non p.Gly551Asp gating mutations treated with ivacaftor. Journal of Cystic Fibrosis. 16(1). 45–48. 14 indexed citations

20.

Avriel, Avital, Eliezer Avinoach, Lone S. Avnon, et al.. (2012). Major respiratory adverse events after laparascopic gastric banding surgery for morbid obesity. Respiratory Medicine. 106(8). 1192–1198. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact